154
Participants
Start Date
February 1, 2020
Primary Completion Date
August 31, 2020
Study Completion Date
June 30, 2021
Baricitinib Oral Tablet
Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
Tocilizumab Injection
Tocilizumab was administered by a single intravenous dose of 400 mg
Netakimab
Netakimab was administered by a single subcutaneous injection of 120 mg
Standard of care therapy
SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
City Clinical Hospital No. 52 of the Department of Health of the City of Moscow, Moscow
Pirogov Russian National Research Medical University, Moscow
City Clinical Hospital No.52 of Moscow Healthcare Department
OTHER
Pirogov Russian National Research Medical University
OTHER